Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.53 |
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | LCK | P06239 | 5/20 | 0.48 |
| ▸ | JAK1 | P23458 | 4/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | GPR4 | P46093 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27227021 | 0.86 | JAK3 (0.40) | JAK3CTSKLCKJAK1JAK2 | |
| SCHEMBL2564595 | 0.85 | CTSK (0.52) | JAK3CTSKLCKGPR4 | |
| SCHEMBL27226227 | 0.79 | GPR119 (0.43) | JAK3CTSKLCKJAK1JAK2 | |
| SCHEMBL31627588 | 0.78 | CTSK (0.38) | JAK3CTSKIRAK4 | |
| SCHEMBL2228524 | 0.76 | CTSK (0.50) | CTSKGPR4 | |
| SCHEMBL27227115 | 0.74 | GPR119 (0.64) | — | |
| SCHEMBL151125 | 0.72 | JAK3 (0.38) | JAK3CTSKJAK1JAK2LRRK2 | |
| SCHEMBL5794080 | 0.71 | CTSK (0.51) | CTSKGPR4 | |
| SCHEMBL13922645 | 0.69 | JAK3 (0.51) | JAK3LCKJAK1JAK2LRRK2 | |
| SCHEMBL14858089 | 0.69 | LRRK2 (0.46) | JAK3LCKJAK1JAK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | JAK3 1252/4885CTSK 2726/4885LCK 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.